Undisclosed ARID1B degrader
/ Foghorn Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
October 30, 2025
Foghorn is developing a Selective ARID1B degrader that is advancing towards in vivo proof of concept in 2026. Key program updates include:
(Foghorn Press Release)
- "Developed VHL and cereblon based bifunctional degraders with potential for oral delivery; Selective degradation of ARID1B achieved; Modulation of downstream target genes following ARID1B degradation"
Preclinical • Solid Tumor
August 05, 2025
Program Overview and Upcoming Milestones
(GlobeNewswire)
- "Continued progress on Selective EP300 degrader and Selective ARID1B degrader, with program updates expected in Q4 2025...Selective CBP degrader program....On track for IND-enabling studies, targeting an IND in 2026."
IND • Preclinical • Diffuse Large B Cell Lymphoma • Estrogen Receptor Positive Breast Cancer • Hematological Malignancies • Multiple Myeloma • Solid Tumor
May 14, 2025
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
(GlobeNewswire)
- "Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026; Continued progress on Selective EP300 degrader and Selective ARID1B degrader with program updates expected in H2 2025."
IND • Preclinical • Oncology
January 13, 2025
Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
(GlobeNewswire)
- "Selective ARID1B degrader program: Developed highly potent and selective binders. Preclinical data demonstrated potent and selective small molecule binders to ARID1B; Selective degradation of ARID1B achieved. Foghorn has successfully selectively degraded ARID1B and expects to provide an update on the Selective ARID1B degrader program in 2025."
Preclinical • Bladder Cancer • Colorectal Cancer • Endometrial Cancer • Ovarian Cancer • Urothelial Cancer
1 to 4
Of
4
Go to page
1